FindTrial
Sign In

DHATUPAKA ASSOCIATION IN PATIENTS OF BAHUPITTA KAMALA (JAUNDICE)

DESCRIPTIVE STUDY OF ASSOCIATION OF DHATUPAKA IN PATIENTS OF BAHUPITTA KAMALA (JAUNDICE) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/102201
Enrollment
40
Registered
2026-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K769- Liver disease, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Tilak Ayurveda Mahavidyalaya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: INCLUSION CRITERIA: a) Participants who are dignosed for Bahupitta Kamala (Jaundice). b) Irrespective of sex, marital status, socioeconomic status, race, religion. c) Participants diagnosed for Bahupitta Kamala (Jaundice) using LFT Test. d) age group 18- 60 years (Including both the genders).

Exclusion criteria

Exclusion criteria: 1)Participants having obstructive jaundice. 2)Participants suffering from major illness who needs intensive care. 3)Drug induced jaundice 4)Pregnancy and lactating Females

Design outcomes

Primary

MeasureTime frame
To study association of Dhatupaka lakshana in bahupitta kamala (Jaundice).Timepoint: 18 Months 0 Weeks—

Secondary

MeasureTime frame
1)To study the status of Agni and Dhatwagni in patients of Bahupitta Kamala (Jaundice). Timepoint: 18 Months 0 Weeks;2)To study the srotas dushti in patients of Bahupitta kamala (Jaundice)Timepoint: 18 Months 0 Weeks;3) To study the association of laboratory finding of liver function test and dhatupak lakshans in bahupitta kamala.Timepoint: 18 Months 0 Weeks—

Countries

India

Contacts

Public ContactDrVidya Naik

Tilak Ayurveda Mahavidyalaya, pune

vidya.r.naik@gmail.com9422003150

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026